Join OHE at ISPOR: MCDA, Risk Sharing and Value-Based Pricing

Join OHE at ISPOR to discuss multiple criteria decision analysis, value based pricing, risk sharing, post-approval data collection and other key topics in HTA and health care decision making.

The 14^th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will be held in Madrid on 5-8 November.

Profs Towse and Devlin

 

OHE’s Nancy Devlin is the workshop committee co-chair for the Congress. Nancy also will be involved in two presentations that address the potential for using multi-criteria decision analysis (MCDA) as an aid in decision making about the use of new health care technologies. Both build on OHE’s research, published in its 2011 primer on MCDA.

At the workshop on ‘Multiple Criteria Decision Analyses for Health Technology Assessment’, Nancy will present the various methods and approaches to MCDA and how these might be used to more explicating incorporate cost effectiveness and other considerations into decision processes.  Nancy will be the moderator for an issues panel that will debate the topic ‘Multi-Criteria Decision Analysis: An Appropriate Framework for Decision Making about New Medical Technologies?’ Panellists will include Mark Sculpher, University of York; Stuart Peacock, University of British Columbia; and Carole Longson, NICE.

Adrian Towse is a speaker at the first plenary session, ‘Pros and Cons of a Centralized European Pricing and Reimbursement Agency,’ moderated by Mark Schulpher, University of York, and including also Hans-Georg Eichler, EMA. Should an agency similar in structure to EMA be established with a centralized procedure for pricing and reimbursement? Should this be a decision making agency or one that only undertakes health technology assessment?  If the latter, what forms of evaluation should be included?

Adrian is leading two other sessions and is a panellist on another. ‘Prospective Observational Studies for Newly Launched Drugs to Assess Relative Effectiveness’, focuses on how best to ensure the accuracy of data collected shortly after a new drug appears on the market.  Participants include Sebastian Schneeweiss, Harvard Medical School; Mark Cziraky, HealthCore; and Wim Goettsch, EUnetHTA.

Again focusing on data collecting after marketing commences, Adrian will moderate ‘Developing Good Research Practices for Performance-Based Risk Sharing’.  The discussion will address the development of ‘good practice’ standards to be applied in performance-based risk-sharing arrangements, including the design, implementation, and evaluation of such an arrangement.  Presented by the ISPOR Performance-Based Risk-Sharing Arrangements Good Research Practices Task Force, the panelists include Lou Garrison, University of Washington; Jens Grueger, Pfizer; Gerard de Pouvourville, the ESSEC Business School; and J.L. (Hans) Severens, Erasmus University Rotterdam.

The OHE has been very involved in issues surrounding value-based pricing, which will become mandatory for all prescription drugs newly marketed in the UK beginning in 2014.  Adrian will be a panelist in the session ‘Value Based Pricing: What Will It Mean in Practice?’  The panel will address a number of practical challenges that will arise from implementing VBP. The panel moderator is John Brazier, University of Sheffield; the other panelists are Karl Claxton, University of York and Jens Grueger, Pfizer.

With Lou Garrison and Josh Carlson of the University of Washington, Adrian will be presenting an intermediate-level short course, ‘Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products’.  Both payers and producers of medical products show a significant and growing interest in payment schemes that involve elements of ‘pay-for-performance’ or ‘risk-sharing’.  Despite their intrinsic appeal, barriers to implementation are substantial. The course covers both theory and practice, including several examples of performance-based schemes from Europe, the United States, and Australia.  An interactive session using a hypothetical case study will illustrate a systematic approach to weighing applicability and feasibility.